Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Forma Therapeutics Holdings, Inc. FMTX
$20.01
На 18:02, 12 мая 2023
-0.05%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
20.28
-
week52low
4.95
-
Revenue
0
-
P/E TTM
-7
-
Beta
-0.94760900
-
EPS
-3.82100000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 ноя 2022 г. в 01:13
Описание компании
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 27 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 17 авг 2021 г. |
| Craig-Hallum | Buy | 02 авг 2021 г. | |
| SVB Leerink | Outperform | Outperform | 11 июн 2021 г. |
| Oppenheimer | Perform | Outperform | 02 сент 2022 г. |
| Jefferies | Hold | Buy | 02 сент 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 02 сент 2022 г. |
| Credit Suisse | Neutral | Outperform | 02 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Frederick Wayne A.I. | D | 0 | 6750 | 14 окт 2022 г. |
| Frederick Wayne A.I. | D | 0 | 7250 | 14 окт 2022 г. |
| Fanucci Marsha | D | 0 | 6750 | 14 окт 2022 г. |
| Fanucci Marsha | D | 0 | 7250 | 14 окт 2022 г. |
| Potts Jeannette | D | 0 | 37500 | 14 окт 2022 г. |
| Potts Jeannette | D | 0 | 43958 | 14 окт 2022 г. |
| Lesser Brian Andrew | D | 0 | 37500 | 14 окт 2022 г. |
| Lesser Brian Andrew | D | 0 | 42593 | 14 окт 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | D | 0 | 6750 | 14 окт 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | D | 0 | 1511425 | 14 окт 2022 г. |
Новостная лента
Forma Therapeutics shares jump 50%; here is why
Invezz
02 сент 2022 г. в 22:38
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk.
Why Forma Therapeutics Holdings Stock Is On Fire Today
The Motley Fool
01 сент 2022 г. в 14:36
The rare blood disorder specialist is the latest biotech buyout target.
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
Investors Business Daily
01 сент 2022 г. в 12:14
Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion
Pulse2
01 сент 2022 г. в 09:20
Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal
Reuters
01 сент 2022 г. в 08:19
Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.